← FDA DRUG APPROVALS

FDA ANDA · ANDA077339

NAPROXEN

Sponsor: L PERRIGO CO

APPLICATION
ANDA077339
TYPE
ANDA
ORIGINAL APPROVAL
2005-04-27
LATEST ACTION
2009-04-29
ROUTE
ORAL
DOSAGE FORM
TABLET
MARKETING STATUS
Discontinued

Products

NAPROXENDiscontinued
NAPROXEN 500MG · TABLET · ORAL
NAPROXENDiscontinued
NAPROXEN 250MG · TABLET · ORAL
NAPROXENDiscontinued
NAPROXEN 375MG · TABLET · ORAL

Approval history

2009-04-29Labeling · Supplement 6AP
2006-06-15Labeling · Supplement 2AP
2006-02-17Labeling · Supplement 1AP
2005-04-27OriginalAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →